Granulocyte Colony Stimulating Factor in Neutropenic Patients

It is worth noting that GCSF is a natural hormone that everyone secretes to regulate cell number. Pseudo-synthesis synthesized in the laboratory has the same chemical properties and effects in the body as the naturally occurring form. The main difference between the molecules is explained in the article titled Filgrastim. A review of its pharmacological properties and its therapeutic effect on neutropenia is that synthetic GCSF contains an N-terminal methionine residue and is not glycosylated.

When neutropenia (primary prevention) is expected, granulocyte colony stimulating factor (CSF) has been widely evaluated for preventive cytotoxic chemotherapy after prophylactic use. Following the previous chemotherapy cycle that caused neutropenia (secondary prevention), CSF was also evaluated for preventive use during retreatment and evaluated for neutrality caused by severe chemotherapy in patients without fever It has been shown to be minimized. Degree and duration of neutropenia (without febrile neutropenia). The use of thermochemotherapy for neutropenia is not recommended. However, in most clinical settings, the prophylactic use of granulocyte CSF has not been shown to affect survival.

Granulocyte colony stimulating factor has been proposed as a drug for stimulating the liver regeneration of alcoholic hepatitis patients by promoting the transfer of bone marrow derived stem cells to the liver. A central study from India showed that patients who received granulocyte colony stimulating factor treatment on day 90 had survival benefits [29]. However, the use of this study in alcoholic hepatitis patients is experimental. Other treatments that are receiving treatment for alcoholic hepatitis but have not been found to be effective include antioxidants such as propylthiouracil, infliximab, insulin and glucagon, calcium channel blockers, vitamin E, S-adenosine included. L-methionine, or silymarin is the active ingredient of milk thistle.

Granocyte colony stimulating factor (G-CSF) has been introduced in clinical trials of stroke patients, and it has been demonstrated that 5-day G-CSF treatment improves the neurological score and metabolic activity of the infarct area. G-CSF was administered to chronic stroke patients without adverse events. The use of EPO and G - CSF in patients with brain injury can exert synergistic effects on tissue plasticity and promotion of angiogenesis, neurogenesis and function recovery. Stroke patients and stroke patients have good resistance to the correlation between EPO and G-CSF

¿ 1/2 neutropenia is defined as a decrease in the absolute number of all circulating cells (neutrophils, eosinophils, basophils) within the granulocyte family, neutropenia Almost all patients are neutral. Because the number of neutrophils is much greater than the number of eosinophils and basophils, the number of cells decreases. Disease related predictors include: lymphatic dehydrogenase elevation (LDH) in patients with lymphoid reticulopathy, bone marrow failure due to abnormal tissue replacement of hematopoietic tissue 19, lymphocytopenia 20, 21 and late stage of late stage malignancy 13, 16, 20 1/222